PERCEPTIVE ADVISORS LLC
CIK 1224962 · last filed 2026-08-27
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Loading insider history…
Disclosed Exposure
$897.91M
Companies
29
Total Filings
77
Lifetime Open-Market Net
$670.43M
Charts
Trading activity, where the exposure sits, and each trade against the stock price.
AEGR price and trades
Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.
Shares held
Shares owned after each reported transaction on this company (direct holdings as reported).
Open-market buying and selling
by monthDollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.
Exposure by company
latestOfficerDirector10% owner* stale (no filing in 3 yrs)
Most recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.
Filer Profile
Reported Address
51 ASTOR PLACE, 10TH FLOORNEW YORK, NY 10003
Phone
(646) 205-5300
State of Incorporation
DE
Formerly Known As
PERCEPTIVE ADVISORS LLC (2003–2026)
Related Filers
Joseph Edelman — 449 joint filings, latest 2026-08-27
PERCEPTIVE LIFE SCIENCES MASTER FUND LTD — 445 joint filings, latest 2026-08-27
Scott Bradley — 49 joint filings, latest 2008-06-19
Michael Cho — 40 joint filings, latest 2008-06-19
Perceptive Xontogeny Venture Fund, LP — 20 joint filings, latest 2025-02-21
LA JOLLA PHARMACEUTICAL CO — 9 joint filings, latest 2020-02-14
Perceptive Credit Advisors, LLC — 9 joint filings, latest 2023-05-01
NEUROCRINE BIOSCIENCES INC — 8 joint filings, latest 2020-02-14
Profile details as reported on the filer's SEC submissions — for individual insiders the address is often in care of the issuer. Related filers are identified from jointly filed SEC submissions and shared reported addresses.
View filings on SEC EDGAR.
Holdings By Company
Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| IMTX | Director | 11,246,516 | $7.13 | $80.24M | $22.50M | 2 | 2026-08-27 |
| MGTX | Director | 11,281,103 | $9.22 | $104.01M | $178.27M | 9 | 2026-06-15 |
| SLDB | Director | 73,107 | $5.89 | $431.0K | $80.60M | 7 | 2026-06-11 |
| ADGM | Director | 9,876,586 | $0.10 | $967.9K | $0 | 1 | 2025-02-14 |
| NAUT | Director | — | $2.63 | — | $0 | 3 | 2024-06-17 |
| VRCA | 10%+ Owner | 672,291 | $3.52 | $2.37M | $54.77M | 2 | 2023-12-26 |
| SOLENO THERAPEUTICS INC (SLNO) Delisted | 10%+ Owner | 2,270,473 | $53.01 | $120.36M | $45.34M | 1 | 2023-09-28 |
| LianBio (LIAN) Delisted | Director | — | $0.32 | — | $0 | 2 | 2023-06-23 |
| Lyra Therapeutics, Inc. (LYRA) Delisted | Director | 25,769 | $0.70 | $18.0K | $36.00M | 2 | 2023-06-02 |
| CHEMBIO DIAGNOSTICS, INC. (CEMI) Delisted | 10%+ Owner | 4,863,334 | $0.46 | $2.21M | $451.2K | 2 | 2023-04-20 |
| ALDX | 10%+ Owner | 10,801,985 | $0.64 | $6.92M | $11.27M | 2 | 2022-08-04 |
| Cerevel Therapeutics Holdings, Inc. (CEREW) Delisted | Director | 4,843,095 | $18.07 | $87.51M | $15.00M | 1 | 2021-07-09 |
| VBI Vaccines Inc/BC (VBIV) Delisted | 10%+ Owner | 0 | $0.07 | $0 | $35.56M | 3 | 2021-06-30 |
| Landos Biopharma, Inc. (LABP) Delisted | Director | 294,177 | $22.93 | $6.75M | $100.00M | 1 | 2021-02-08 |
| Astria Therapeutics, Inc. (CATB) Delisted | Director | — | $8.54 | — | $0 | 1 | 2021-02-03 |
| Motus GI Holdings, Inc. (MOTS) Delisted | 10%+ Owner | 10,702 | $0.00 | $1 | $10.79M | 3 | 2021-01-22 |
| Crinetics Pharmaceuticals, Inc. (CRNX) Delisted | 10%+ Owner | 3,659,381 | $84.95 | $310.86M | $45.00M | 1 | 2020-04-20 |
| ALBIREO PHARMA, INC. (ALBO) Delisted | 10%+ Owner | 1,960,139 | $44.15 | $86.54M | $16.12M | 1 | 2020-02-04 |
| AMICUS THERAPEUTICS, INC. (FOLD) Delisted | 10%+ Owner | 20,724,424 | $14.49 | $300.30M | $0 | 1 | 2019-02-19 |
| LA JOLLA PHARMACEUTICAL CO (LJPC) Delisted | 10%+ Owner | 4,313,611 | $6.22 | $26.83M | $79.13M | 2 | 2018-03-26 |
| Corium International, Inc. (CORI) Delisted | 10%+ Owner | 5,847,133 | — | — | $6.96M | 1 | 2017-07-05 |
| TALPHERA, INC. (ACRX) Delisted | 10%+ Owner | 323,378 | $0.86 | $278.1K | $11.38M | 2 | 2013-11-12 |
| Aegerion Pharmaceuticals, Inc. (AEGR) Delisted | 10%+ Owner | 2,823,426 | — | — | -$153.82M | 4 | 2013-09-09 |
| REPROS THERAPEUTICS INC. (RPRX.Z) Delisted | 10%+ Owner | — | — | — | $0 | 4 | 2013-02-13 |
| SYNAGEVA BIOPHARMA CORP (GEVA) Delisted | 10%+ Owner | 0 | — | — | $0 | 1 | 2011-11-09 |
| REPROS THERAPEUTICS INC. (RPRXZ) Delisted | 10%+ Owner | 1,982,460 | — | — | $12.38M | 3 | 2011-08-24 |
| PENWEST PHARMACEUTICALS CO (PPCO) Delisted | 10%+ Owner | 6,476,446 | — | — | $279.5K | 7 | 2009-03-31 |
| IDEV | 10%+ Owner | 7,891,067 | $89.05 | $702.70M | $5.16M | 2 | 2009-03-09 |
| XTLB | 10%+ Owner | 153,459 | $1.78 | $273.2K | $57.30M | 5 | 2008-06-11 |
Recent Filings · Page 6 of 8
77 filingsInsider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2013-11-04 | TALPHERA, INC. (ACRX) Delisted | Buy (P) | +1,081,980 | $7.47M | EDGAR |
| 2013-09-09 | Aegerion Pharmaceuticals, Inc. (AEGR) Delisted | Mixed | −1,650,000 | -$185.70M | EDGAR |
| 2013-02-13 | REPROS THERAPEUTICS INC. (RPRX.Z) Delisted | Mixed | — | $0 | EDGAR |
| 2013-02-08 | REPROS THERAPEUTICS INC. (RPRX.Z) Delisted | Mixed | — | $0 | EDGAR |
| 2013-02-05 | Aegerion Pharmaceuticals, Inc. (AEGR) Delisted | Buy (P) | +150,000 | $4.17M | EDGAR |
| 2013-01-23 | REPROS THERAPEUTICS INC. (RPRX.Z) Delisted | Sell (S) | — | $0 | EDGAR |
| 2013-01-22 | Aegerion Pharmaceuticals, Inc. (AEGR) Delisted | Buy (P) | +150,000 | $4.14M | EDGAR |
| 2013-01-15 | Aegerion Pharmaceuticals, Inc. (AEGR) Delisted | Buy (P) | +1,425,000 | $38.57M | EDGAR |
| 2013-01-11 | REPROS THERAPEUTICS INC. (RPRX.Z) Delisted | Sell (S) | — | $0 | EDGAR |
| 2011-11-09 | SYNAGEVA BIOPHARMA CORP (GEVA) Delisted | Other (J) | −7,020,000 | $0 | EDGAR |
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.